Cerus (NASDAQ:CERS) will float a new offering of common stock in an underwritten public offering.The pharma company didn't disclose the number of shares that will be offered, nor did it specify how much it intended to raise from the issue. It did say that it intends to use the funds "for clinical development and other research and development activities" connected with its key product, the INTERCEPT Blood System.
Cerus added that it might use some of the proceeds to prepay outstanding monies owed to Comerica Bank for a growth capital loan.
Cowen Group's Cowen & Co. is the sole book-running manager for the issue.
Fool contributor Eric Volkman and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Here's Why Cerus Corporation Rose as Much as 23.6% Today
The biopharma reported third-quarter 2017 results and additional business updates.
Why Cerus Corporation Stock Marched Higher Today
A positive regulatory development sent Cerus' shares higher today.
Here's Why Cerus Corporation Rose as Much as 17.4% Today
The company provided an update on the most pressing issue facing the biopharma stock in 2017.